- XanADu opens five additional study sites in the USA, having a total of 25 sites across the USA, Australia and the UK.
- The new sites are set to accelerate patient enrollment in the study.
- The study is on the efficacy of Xanamen in treating patients with mild Alzheimer’s Disease.
Actinogen Medical (ASX: ACW), a biotech company, has announced the opening of five additional study sites in the USA to its international XanADu study. The sites are for the XanADu Phase II double-blind trials of Xanamen in mild Alzheimer’s Disease. The USA has the highest potential patient population interested in participating in an Alzheimer’s clinical trial. The sites have committed to identifying and screening patients to enrol in the trial, ensuring the study continues to complete patient enrollment by the end of 2018, with the initial results expected in Q2 2019.
XanADu is a Phase II 12-week, randomised, placebo-controlled study being carried out in an additional 20 sites in Australia, the UK and the USA, with 117 patients enrolled to date. The trial will assess the tolerability and efficacy of Xanamen in subjects with mild dementia due to Alzheimer’s disease. There is a strong association between chronic stress and excess cortisol that leads to changes in the brain affecting memory and other hallmarks of Alzheimer’s disease. Xanamen blocks the activity of 11β-HSD1, an enzyme that converts inactive cortisone into its active form, cortisol in the brain. Blocking the activity of the enzyme, therefore, reduces the amount of cortisol in the brain.
About Actinogen Medical Ltd
Actinogen Medical Limited (ASX: ACW) is an Australian, publicly-listed early clinical-stage biotechnology company focused on the treatment of cognitive impairment and Alzheimer’s disease.